- Investor's Business Daily•yesterday
Edwards Lifesciences' fiscal 2017 guidance lagged Wall Street for its heart-valve replacement tech amid fierce competition with Medtronic and Boston Scientific.
- Moody's•2 days agoBoston Scientific Corporation -- Moody's upgrades Boston Scientific's senior unsecured rating to Baa2; outlook is stable
New York, December 07, 2016-- Moody's Investors Service today upgraded Boston Scientific Corporation's senior unsecured rating to Baa2 from Baa3. This action is based on Moody's expectation that Boston ...
- Investor's Business Daily•3 days ago
Edwards Lifesciences 2017 guidance could be somewhat strangled Thursday on Medtronic and Boston Scientific competition.
BSX : Summary for Boston Scientific Corporation C - Yahoo Finance
Boston Scientific Corporation (BSX)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||20.78 x 100|
|Ask||20.86 x 800|
|Day's Range||20.69 - 20.95|
|52 Week Range||15.67 - 24.79|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||392.64|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|